Adding irradiation before transplant improves long-term results and should change practice
Scleroderma with internal organ involvement is a debilitating and lethal autoimmune disorder with few effective treatments. But a study led by Duke Health researchers has found new cause for optimism using an aggressive stem cell transplant regimen.
The researchers, publishing in the Jan. 4 issue of the New England Journal of Medicine, found significantly improved survival among patients with a severe form of scleroderma who underwent chemotherapy, whole body radiation and a stem cell transplant. Patients also had less need for immune suppressant drugs after transplant.
“Scleroderma hardens the skin and connective tissues and in its severe form leads to fatal organ failure, most often the lungs” said lead author Keith Sullivan, M.D., James B. Wyngaarden Professor of Medicine and Cellular Therapy at Duke. “In these severe cases, conventional drug therapies are not very effective long-term, so new approaches are a priority.”
Earlier publications suggested that stem cell transplant might be a viable treatment, using less intensive treatment without irradiation. These studies showed that reduced-intensity stem cell transplant improved survival, but the disease often returned and patient safety remained a concern. As a result, conventional immunosuppressive drug treatment remained the standard of care in the U.S.
In the current study, Sullivan and colleagues developed a transplant conditioning regimen that included high-dose chemotherapy plus whole-body radiation to fully wipe out the patient’s defective immune-forming system, with the aim of improving survival and diminishing the effects of the disease. They limited radiation by shielding patients’ kidneys and lungs while repopulating the blood and immune system.
Thirty-six scleroderma patients were randomly assigned to receive transplant. The regimen was designed to destroy the patients’ defective autoreactive immune system and replace it with their own blood stem cells that had been removed and treated to eliminate self-reacting lymphocytes.
For comparison, 39 additional patients were randomized to receive 12 monthly intravenous injections of cyclophosphamide, a conventional immune suppressing treatment for severe scleroderma.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable.”
The study was conducted over a 10-year period at 26 universities in the United States and Canada. The primary study endpoint at 54 months was a global rank composite score based on a hierarchy of scleroderma features including survival, organ function, quality of life and skin hardening. Results showed significant benefit with transplant: 67 percent of 1,404 pairwise comparisons favored transplant vs. 33 percent favoring cyclophosphamide.
By study endpoint, fewer transplant recipients resumed use of anti-scleroderma drugs (9 percent vs. 44 percent of controls). Overall survival at 72 months was 86 percent after transplant vs. 51 percent after cyclophosphamide — a highly significant benefit.
“These results show that individuals with poor-prognosis scleroderma can improve and live longer and that these advances appear durable,” Sullivan said.
Treatment-related mortality at the study endpoint of 54 months was 3 percent among transplant recipients while cyclophosphamide recipients had no treatment-related deaths. In the short term, transplant recipients also had more serious side effects, such as low blood counts and infections.
“Patients and their doctors should carefully weigh the pros and cons of intensive treatment with stem cell transplant, but this may hopefully set a new standard in this otherwise devastating autoimmune disease,” Sullivan said. “These advances show the value of medical research and clinical trials in finding better therapies to advance health.”
The Latest on: Stem cell transplant
- Opinion: We need more donors to build a diverse stem cell registryon November 30, 2019 at 4:11 am
In 2018, she was fortunate to match with her sibling — fortunate because only one in four patients match with a family member. Every year, hundreds of Canadian patients require a life-saving stem cell ...
- Targeted stem-cell attack could make transplants saferon November 29, 2019 at 7:37 am
Scientists are experimenting with ways to selectively target the body’s blood-making cells for destruction. Early studies in animals and people suggest that the approach could make blood stem-cell ...
- Single cell census of human kidney organoids shows reproducibility and diminished off-target cells after transplantationon November 29, 2019 at 2:19 am
Day 28 mature kidney organoids were washed twice with PBS and incubated with Accumax (Stem Cell Technologies, no. 07921 ... A similar approach was also used to combine ThF organoids from days 0, 7 and ...
- Texas family celebrates at NIH after daughter’s transplant, chance for cureon November 28, 2019 at 4:52 pm
They also learned patients had been cured through stem cell transplants. “With the word cure, we had hope,” Katie said. The journey had its highs and lows. The Ballards wondered if they would find ...
- 33-year-old Charleston man needed a second stem cell transplant. He hopes this one works.on November 28, 2019 at 6:16 am
Then, in 2017, doctors transplanted stem cells from Russell's own bone marrow in a bid to cure his disease for good. But the transplant didn't work. On Oct. 23, he received another stem cell ...
- Every 13th man has a hair transplant according to Bookimed studyon November 28, 2019 at 3:26 am
Except for the traditional hair transplant methods as FUE (follicular unit extraction) and FUT (follicular unit transplant), specialists apply stem cell hair restoration and robotic operation. Stem ...
- Researchers identify protein that governs human blood stem cell self-renewalon November 28, 2019 at 2:26 am
Bone marrow transplants have been used for decades to treat people with some diseases of ... Using pluripotent stem cells, they made blood stem cell-like cells that lacked the ability to self-renew ...
- Kyoto University eyes human iPS cell transplant to heal knee jointson November 27, 2019 at 11:45 pm
A Kyoto University research team aims to conduct a clinical trial to transplant cartilage made from induced pluripotent stem cells into patients with damaged knee joints ... For the project, ...
- Stem cell donation from American is lifesaver for Scottish toton November 27, 2019 at 8:30 pm
And yesterday she turned two years old with the best birthday present her parents could hope for – being in remission from leukaemia after the stem cell transplant which used umbilical cord blood from ...
- Activation of the Immune System Underlies Cardiac Cell Therapieson November 27, 2019 at 12:45 pm
How the cells help has been a mystery. A paper in Nature today (November 27) shows that activation of an innate immune response can explain, and even recapitulate, the beneficial effects of stem cell ...
via Google News and Bing News